MedPiper Technologies vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru Diagnostics-as-a-Service API connecting 10,000+ India labs for telehealth and insurers; YC W20 $3.28M at 91% YoY growth enabling digital health platforms to embed diagnostics without logistics.
About
MedPiper Technologies is a Bengaluru-based Diagnostics-as-a-Service (DaaS) platform — India's first comprehensive diagnostic infrastructure API — enabling insurers, health plans, telehealth providers, and healthcare organizations to embed diagnostic services (lab tests, radiology, home sample collection) into their digital health workflows through a single white-label integration. Founded in 2020 and backed by Y Combinator (W20) with $3.28 million raised, MedPiper generates ₹5.57 crore (approximately $670,000 USD) in annual revenue with 91% year-over-year growth, serving the digital health ecosystem as the infrastructure layer that connects healthcare platforms to India's fragmented diagnostic laboratory network.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.